Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
CDNL has dropped 45% over the past month to $21.12, yet analysts hold five buy ratings with a mean target of $54.25, and a cluster of insiders spent nearly $10 million buying shares in August when the stock was trading near $40.
The most mechanically pressing issue now is index exposure. ORTEX forecasts a 92% probability that Cardinal is deleted from the MSCI World Small, MSCI USA IMI, MSCI USA Small, and MSCI World IMI indices at the November 2026 Quarterly Review. The rank date is October 19. If confirmed on November 11, index trackers would need to sell roughly $40 million to $48 million combined across the four benchmarks, with trades executing November 30 and effective December 1. The price that flips the decision is $21.02: Cardinal closed Thursday at $21.12, just ten cents above that line. Daily volatility is running at 7.6%, so the stock is within a single ordinary session of triggering the exit.
The lending market does not reflect any particular alarm about a short squeeze. Availability has tightened this week, falling to around 129% from 176% a week ago, meaning there are still roughly 1.3 shares available to borrow for every share already borrowed. Borrowing costs are low at 0.58% annualised. Short interest is essentially flat, down about 1.4% on the week to roughly 2.51 million shares. The ORTEX short score has drifted higher to 66.6, near the top of its recent range, but that reading reflects the price damage rather than a surge in fresh positioning. Options are slightly more call-heavy than usual: the put/call ratio is 0.65, a notch below its 20-day average of 0.68, not the defensive pile-up one might expect given the price action.
The Street remains stubbornly constructive, and that gap between analyst targets and the current price is genuinely wide. All five covering analysts rate the stock a buy. Truist Securities initiated coverage on September 25 at Buy with a $40 target. After the August earnings miss, Stifel cut its target from $63 to $52 and Oppenheimer trimmed from $80 to $70, but both maintained positive ratings. The bull case rests on Cardinal's vertically integrated model, combining wet utilities, grading, paving and site services in-house, and a roll-up strategy buying tuck-ins at 4 to 5 times EBITDA. Q1 revenue came in at $226.9 million, up 114% year on year, with backlog at $866 million. The bear case is blunter: residential construction exposure remains soft, the adjusted EBITDA margin printed at 12.4%, weather and execution issues hurt profitability, and a June equity issuance damaged confidence before the August miss compounded it. The EV/EBITDA multiple has compressed to 3.6 times over the past month, and the PE ratio has shed more than eight points in 30 days, now at 8.2 times.
What makes the insider purchases from August 14 worth noting is the breadth. The CEO, CFO, COO, three directors, and a fourth director all bought open-market shares on the same day, with no 10b5-1 plan attached to any of the transactions. The total across all participants came to roughly $5.5 million in a single session. A further purchase on August 17 brought the 90-day net to $9.6 million across 241,597 shares. All of those trades were done between $36.53 and $39.77 per share, well above Thursday's close. Founding shareholders are also sizeable: CEO Jeremy Spivey held 45% of shares as of his February 13D/G filing, and CFO Michael Rowe held 29%, though stakes are as last disclosed and these are event-driven filings around the 5% threshold.
The key date is October 19, when MSCI takes its market-cap snapshot for the November review. Whether Cardinal closes above or below $21.02 on that day determines whether the deletion proceeds to announcement on November 11, the same day earnings are scheduled. The coincidence of the index announcement date and the earnings date means November 11 concentrates two distinct catalysts into a single session.
See the live data behind this article on ORTEX.
Open CDNL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
